30 Years On - Developing Cost–Effective Drug Discovery Programs Remains the No.1 Challenge
Add bookmark
Dr. Andrew Alexander Parsons, Director at Reciprocal Minds Limited and former VP
Preclinical Drug Development and External Discovery at GSK, discusses current and future burning issues in the pharmaceutical industry.
Pharma IQ: What in your opinion are the major challenges today for enhancing early-stage development and what major trends can you recognize in the MedChem partnership market?
A Parsons: The increasing cost of medicines development with limited/no increase in...
